Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study.
Wael HafezAhmed AbdelrahmanPublished in: Antibiotics (Basel, Switzerland) (2022)
(1) Background: The efficacy of tocilizumab in COVID-19 has been doubted. The study aimed to investigate factors affecting disease stability and response to tocilizumab among severe COVID-19 patients. (2) Methods: This was a cohort study of 70 severe COVID-19 patients at NMC Royal Hospital, UAE, from April to June 2020. (3) Results: Elderly patients and those with cardiovascular comorbidities had a higher risk of unstable COVID-19 ( p = 0.025). Regarding tocilizumab therapy timing, compared to the critical group receiving tocilizumab, the unstable severe patients receiving tocilizumab had a significantly higher rate of improvement (86%). In contrast, the late critical subgroup showed a significantly increased mortality rate (52.9%). The risk for secondary infection and adverse events following tocilizumab was higher in the late critical group than in the unstable severe and early critical groups ( p = 0.024 and p = 0.006, respectively). Therapeutic doses of anticoagulation and high-dose vitamin D were correlated with better outcomes than the prophylactic dose and the treatment dose of vitamin D ( p < 0.001 and p = 0.07, respectively). (4) Conclusions: elderly patients and those with cardiovascular disease developed unstable COVID-19. Tocilizumab is a potentially effective choice against severe and critical COVID-19. Early tocilizumab administration combined with therapeutic dose anticoagulation and high vitamin D doses could improve the patients' outcomes.
Keyphrases
- rheumatoid arthritis
- coronavirus disease
- sars cov
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- early onset
- cardiovascular disease
- disease activity
- high dose
- end stage renal disease
- respiratory syndrome coronavirus
- chronic kidney disease
- healthcare
- ejection fraction
- atrial fibrillation
- clinical trial
- venous thromboembolism
- magnetic resonance
- randomized controlled trial
- magnetic resonance imaging
- systemic lupus erythematosus
- stem cells
- newly diagnosed
- coronary artery disease
- cardiovascular events
- adipose tissue
- patient reported outcomes
- stem cell transplantation
- mesenchymal stem cells
- replacement therapy
- acute care
- smoking cessation
- study protocol
- placebo controlled